Trials / Completed
CompletedNCT01226277
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma
An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered Daily in Patients With Refractory Solid Tumors or Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter, Phase I dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics (PK) of GDC-0917 in patients with refractory solid tumors or lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GDC-0917 | Oral repeating dose |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2012-09-01
- Completion
- 2012-09-01
- First posted
- 2010-10-22
- Last updated
- 2016-11-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01226277. Inclusion in this directory is not an endorsement.